Martin Holst Lange, Executive Vice President, Development, Novo Nordisk, highlighted during the press briefing that their ...

Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Still, Novo is steadfast in its goal to eventually become a leader in the space, the company’s EVP of rare disease, Ludovic ...

Novo Nordisk is doing exceptionally well in the ... which is a long-acting growth hormone. Thanks to less frequent injections and the fact that it is not inferior to Norditropin, Sogroya is ...

Novo Nordisk has ... version of parathyroid hormone (PTH), which is for the treatment of hypoparathyroidism in adults, and Skytrofa (lonapegsomatropin), a long-acting growth hormone for children ...

Novo Nordisk's weight loss drug Wegovy is linked to an increased risk of hair loss, a study suggests. Meanwhile, Dexcom ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest dose of the drug lost 15.7% of their weight.

Novo Nordisk said on Wednesday it would begin selling its weight-loss drug Wegovy at a discounted price of $499 per month to patients paying cash, as it grapples with shifts to the competitive ...

Double-digit growth in revenue and operating ... 43.30% of the world market for this life-saving hormone. It has been about 100 years since Novo Nordisk marketed the first effective drug for ...

The company's GLP-1 receptor agonist products, Ozempic (semaglutide) for type 2 diabetes and Wegovy (semaglutide) for weight management, have been driving significant growth and market share gains. In ...